グラウコスに関するコメント

Last week’s PDUFAs:
$アークティス・バイオセラピューティクス(ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$メルク(MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$グラウコス(GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$メルク(MRK.US)$ : Approved ...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPRセラピューティクス(CRSP.US)$$バーテックス・ファーマシューティカルズ(VRTX.US)$$オプティノーズ(OPTN.US)$$アークティス・バイオセラピューティクス(ARQT.US)$$カリディタス・セラピューティクス(CALT.US)$$ブルーバード・バイオ(BLUE.US)$$グラウコス(GKOS.US)$$アイオニス・ファーマシューティカルズ(IONS.US)$$アムジェン(AMGN.US)$$メルク(MRK.US)$

$グラウコス(GKOS.US)$
im seeing some decent chart upside here
thoughts?

$Ultra Nasdaq Biotechnology Proshares(BIB.US)$ was climbing 1.5%.
$サイスパーク(SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$グラウコス(GKOS.US)$ gained 6% after We...

Gainers:
• $カヌー(GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $アルデイラ・セラピューティクス(ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $ウエストポート・フューエル・システムズ(WPRT.US)$ +10.9% (awarded 38 mln program)
• $グリニッジ・ライフサイエンシズ(GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...